Information Provided By: 
Fly News Breaks for October 1, 2015
SNY, ALNY
Oct 1, 2015 | 13:00 EDT
Piper Jaffray analyst Edward Tenthoff said it was not surprising that Alnylam (ALNY) partner Sanofi (SNY) exercised an option on ALN-AT3 for treatment of hemophilia outside of North America and Western Europe following the "impressive" Phase I data presented earlier this year. The analyst views the recent weakness in Alnylam shares as an opportunity to buy the "leading RNAi name" and reiterates an Overweight rating and $184 price target on the stock.
News For ALNY;SNY From the Last 2 Days
ALNY
Apr 23, 2024 | 07:17 EDT
ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).
